



Sessie 5 Kostbare geneesmiddelen (te) duur?

Prog.	Dossierrnr	Titel	Projectleider/ instelling	Einddatum
DG	152001001	Treatment of Fabry disease with the orphan drugs agalsidase alfa en agalsidase beta in the Netherlands: Health Technology Assessment related to Orphan Drug reimbursement policy.	Prof. dr. C.E.M. Hollak/ AMC	1-10-2011
DG	152001002	Cost-effectiveness and outcome of current treatment strategies in exudative age-related macular degeneration	Dr. J.S.A.G. Schouten / Maastricht Universitair Medisch Centrum+	16-12-2011
DG	152001003	Mucopolysaccharidosis type VI: Natural course, effects of enzyme therapy and health economic aspects. Long-term follow-up of untreated patients and patients receiving commercially available galsulfase (Naglazyme)	Prof. A.T. van der Ploeg / Sophia Kinderziekenhuis	1-10-2011
DG	152001004	Mucopolysaccharidosis type II: Natural course, effects of enzyme therapy and health economic aspects. Long-term follow-up of untreated patients and patients receiving commercially available Idursulfase (Elaprase)	Prof. A.T. van der Ploeg / Sophia Kinderziekenhuis	1-10-2011
DG	152001005	Effects and health economic aspects of enzyme therapy in children and adults with pompe disease. Long term follow-up of patients receiving commercially available alglucosidase alfa (Myozyme).	Prof. A.T. van der Ploeg / Sophia Kinderziekenhuis	1-10-2011
DG	152001006	An independent prospective randomised controlled trial comparing the efficacy and cost effectiveness of infliximab and etanercept in 'high need' patients with moderate to severe chronic plaque type psoriasis	Dr. Ph.I. Spuls / AMC	1-10-2012
DG	152001007	Impact of new systemic treatments of patients with hematological malignancies in the Netherlands: population-based cohort studies of process and outcome as a basis for assessments of cost-effectiveness.	Prof. C.A. Uyl-de Groot / Erasmus Universiteit Rotterdam	1-10-2014
DG	152001008	More customized, cost-effective use of biologicals in treatment of rheumatoid arthritis.	Dr. A.C.A. Marijnissen / UMCU	1-1-2015
DG	152001009	Real world efficiency of Bevacizumab in Advanced Breast Cancer	Prof. dr. V.C.G. Tjan-Heijnen / MUMC	1-12-2012
DG	152001010	A multi-centre cost-effectiveness evaluation of a novel treatment option in the Netherlands: Photo Dynamic Therapy with temoporfine for the treatment of advanced incurable head and neck cancers, for whom prior conventional treatments have failed.	Prof. dr. I.B. Tan / NKI	1-2-2013
DG	152001011	National registry for the evaluation of treatment patterns, guideline adherence and use of expensive anti-fungals.	Prof. dr. B.J. Kullberg / UMC St Radboud	20-4-2012
DG	152001012	A cost-effectiveness and quality of life study on MAL-PDT in actinic keratoses and basal cell carcinoma	Dr. M.J.P. Gerritsen / UMC St Radboud	31-12-2013
DG	152001013	Basal cell carcinoma and actinic keratoses in the Netherlands: how often do they occur and who are at risk?	Dr. T.E.C. Nijsten / Erasmus MC	1-1-2013
DG	152001014	Impact of new approaches to pharmacological management of patients with renal cell carcinoma: a population-based study of process and outcomes in The Netherlands.	Prof. C.A. Uyl-de Groot / Erasmus Universiteit Rotterdam	1-4-2014
DG	152001015	SELDI-TOF analysis to predicted rituximab treatment outcome in rheumatoid arthritis patients.	Dr. M.J.H. Coenen / UMC St Radboud	1-6-2015
DG	152001016	Real world Efficiency of Trastuzumab in Early Breast Cancer	Prof. dr. V.C.G. Tjan-Heijnen / MUMC	1-5-2013
DG	152001017	Biomarkers for improving the cost-effectiveness and safety of pemetrexed	Prof. dr. B.H.C. Stricker / Erasmus MC	1-11-2015
DG	152001019	Impact of new approaches to the management of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (RM SCCHN: a population-based study of process and outcomes in The Netherlands.	Prof. C.A. Uyl-de Groot / Erasmus Universiteit	1-11-2013
DG	152001020	Treatment Sequencing in Multiple Myeloma: modeling the disease and evaluating cost-efficacy vs. cost-effectiveness	Prof. dr. P. Sonneveld / Erasmus MC	1-5-2015
DG	152001021	Eculizumab in patients with classic PNH: a cost effectivity study.	Dr. P. Muus / UMC St Radboud	1-4-2015



DG	152001023	Canakinumab in Cryopyrin-Associated Periodic Syndrome	Dr. A. Simon / UMC St Radboud	1-12-2016
DG	152041001	Potential optimisation of (Expediency) and Effectiveness of TNF-blockers	Dr. T.L.Th.A. Jansen / UMC St Radboud	1-11-2015
DG	152041002	Communicatieproject bij studie POEET	Drs. G.E.M.P. Willemsen - de Mey / Willemsen Consultancy	1-11-2015
DG	1520010011	Practical approach to improve the evaluation of orphan medicinal products: the case of Fabry disease	Prof. dr. C.E.M. Hollak	1-3-2015
DG	1520010051	Towards a more sensible development and meaningful implementation of orphan drugs	Prof. A.T. van der Ploeg	1-6-2016
RR	836007001	Haalbaarheidsstudie Dure Geneesmiddelen PatiëntenRegisters	Dr. L.E.A. Jansen-Landheer	1-7-2013
Dof	170885605	Comparative cost minimization study in treatment of superficial basal cell carcinoma: photodynamic therapy versus imiquimod versus fluorouracil, a randomized controlled trial	Dr. N. Kelleners-Smeets	1-8-2011
Dof	170885605	Comparative cost minimization study in treatment of superficial basal cell carcinoma: photodynamic therapy versus imiquimod versus fluorouracil, a randomized controlled trial	Dr. N. Kelleners-Smeets	1-8-2011
Dof	170995001	The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritis	Prof. dr. P.L.C.M. van Riel	1-8-2015
Dof	1708856051	Implementatie resultaten: Comparative cost minimization study in treatment of superficial basal cell carcinoma: photodynamic therapy versus imiquimod versus fluorouracil, a randomized controlled trial (170885605)	Dr. N. Kelleners-Smeets	1-8-2015
Dof	170885606	Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration (COSD).	Dr. R.O. Schlingemann	1-12-2012
Dof	171202018	Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with retinal vein occlusions(The BRVO study)	Schlingemann	1-4-2016
Dof	171202019	Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with diabetic macular edema (The BRDME Study)	Schlingemann	1-4-2016
DG	152031001	Botuline Toxine Review	Dr. J. van Limbeek / Sint Maartenskliniek	31-12-2013
DG	152031002	Trastuzumab en taxanen in de behandeling van gemetastaseerd borstkanker	Prof. dr. V.C.G. Tjan-Heijnen / MUMC	31-12-2013
DG	152031003	OFFERTE. In het kader van het Programma Dure Geneesmiddelen voor uitvoering van review betreffende de ziekten van Crohn, Bechterew en artritis psoriatica met de focus op Infliximab (remicade) voor deze indicatie.	Prof. Dr. M.P. Peppelenbosch / Erasmus MC	31-12-2013
DG	152031004	Botulinetoxine behandeling bij focale dystonie	Prof. Dr. M.A.J. de Koning-Tijssen / AMC	31-12-2013
DG	152031005	Review of docetaxel, gemcitabine, paclitaxel and vinorelbine for the treatment of non-small cell lung cancer.	Prof. Dr. C.A. Uyl-de Groot / Erasmus Universiteit	31-12-2013
DG	152031006	Review of irinotecan, oxaliplatin, docetaxel and bevacizumab for the treatment of colorectal and gastric cancer.	Prof. Dr. C.A. Uyl-de Groot / Erasmus Universiteit	31-12-2013
DG	152031007	Review of bortezomib and other (expensive) drugs for the treatment of multiple myeloma.	Prof. Dr. C.A. Uyl-de Groot / Erasmus Universiteit	31-12-2013
DG	152031008	Offerte voor een review over het gebruik van Laronidase bij de ziekte Mucopolysaccharidose type	Prof. Dr. F.A. Wijburg / AMC	31-12-2013
DG	152031009	Review dure geneesmiddelen bij reumatoïde artritis	Mr. Drs. D.W.M. Jansen / Stichting Holding RCA/JBI	31-12-2013
DG	152031010	Review of docetaxel for the treatment of prostate cancer and gemcitabine for the treatment of pancreatic cancer.	Drs. H.M. Westgeest / VUMC	31-12-2013
DG	152031011	Review van overige vast tumoren	Dr. J.G. Hugtenburg / VUMC	31-12-2013
DG	152031012	Review plaatsbepaling immunoglobulines op beleidsregel dure geneesmiddelen	Dr. A. Simon / Radboudumc	31-12-2013